Eagle Pharmaceuticals, Inc. (EGRX)
EGRX moved a median of 0.00% 30 minutes after news, and -0.06% by the close. How EGRX actually reacts to news — the realized, point-in-time move the market made, measured across 555 labeled events over the last three years with zero look-ahead.
EGRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 532 |
| 30-min | 0.00% | 44% | 540 |
| 60-min | -0.20% | 41% | 538 |
| to close | -0.06% | 46% | 544 |
| Middle 50% of EGRX reactions | -1.62% to +0.92% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 555 |
Half of all Eagle Pharmaceuticals, Inc. news events land between -1.62% and +0.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when EGRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EGRX's baseline. Nothing else.
Recent EGRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | — | — | |
| Eagle Pharmaceuticals Announces Divestiture of Barhemsys | Press release | GlobeNewswire | +0.00% | — | |
| HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS | Press release | PR Newswire | — | +0.00% | |
| Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | — | — | |
| Indian Society of Anaesthesiologists Hosts Nationwide Launch of Ryanodex® in India | Press release | PR Web | — | — | |
| ACA Pharma Announces 2026 China NPP Group Procurement Priority List for Orphan and Clinically Urgent Drugs | Press release | PR Web | — | — | |
| Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements | Press release | GlobeNewswire | — | — | |
| Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements | Press release | GlobeNewswire | — | — | |
| Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years | Press release | GlobeNewswire | +0.46% | -5.41% | |
| Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors | Press release | GlobeNewswire | — | — | |
| Eagle Pharmaceuticals Announces 2025 Annual Meeting Date | Press release | GlobeNewswire | +1.96% | — | |
| ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau | Press release | PR Web | — | +0.00% | |
| Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties | Press release | GlobeNewswire | +18.22% | +37.78% | |
| Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan | Press release | GlobeNewswire | +0.00% | +40.78% | |
| Form 15-12G EAGLE PHARMACEUTICALS, | SEC filing · Form 15-12G | SEC EDGAR | +76.44% | +76.44% | |
| Form EFFECT EAGLE PHARMACEUTICALS, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.67% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +183.55% | |
| Form POS AM EAGLE PHARMACEUTICALS, | SEC filing · Form POS | SEC EDGAR | +0.00% | -2.74% | |
| Form RW EAGLE PHARMACEUTICALS, | SEC filing · Form RW | SEC EDGAR | +0.00% | -2.74% | |
| Form S-8 POS EAGLE PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.74% | |
| Form 25 EAGLE PHARMACEUTICALS, | SEC filing · Form 25 | SEC EDGAR | +0.00% | +183.55% | |
| Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration | Press release | GlobeNewswire | +0.00% | +30.21% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +30.21% | |
| Form NT 10-Q EAGLE PHARMACEUTICALS, For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | -16.67% | |
| Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer | Press release | GlobeNewswire | +0.00% | +12.51% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Nov 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +12.51% | |
| Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan | Press release | GlobeNewswire | +0.00% | +20.00% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +20.00% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Sep 27 | SEC filing · Form 8-K | SEC EDGAR | -12.23% | -23.02% | |
| Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq | Press release | GlobeNewswire | +0.86% | +11.83% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +11.83% | |
| Form NT 10-Q EAGLE PHARMACEUTICALS, For: Jun 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | -1.22% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +5.46% | +3.56% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Jul 03 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | -1.31% | |
| Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), and QuidelOrtho Corporation (NASDAQ: QDEL) | Press release | Accesswire | -1.52% | +1.62% | |
| Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS) | Press release | Accesswire | +0.00% | +0.52% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -2.58% | -13.47% | |
| Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq | Press release | GlobeNewswire | +0.00% | -11.39% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -11.39% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +2.46% | -1.60% | |
| Form NT 10-Q EAGLE PHARMACEUTICALS, For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -0.88% | |
| Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual M | Press release | GlobeNewswire | -0.74% | +0.99% | |
| Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida | Press release | GlobeNewswire | -1.71% | +18.18% | |
| Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K | Press release | GlobeNewswire | -1.71% | +18.18% | |
| Form 8-K EAGLE PHARMACEUTICALS, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -1.71% | +18.18% | |
| Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE) | Press release | Accesswire | +0.00% | +0.10% | |
| Form NT 10-K EAGLE PHARMACEUTICALS, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +1.09% | -5.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EGRX section they belong to.
Where else EGRX is measured.
EGRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | 558 | -0.32% | 41% |
| PERNIX THERAPEUTICS HOLDINGS (PTX) | 557 | -0.19% | 41% |
| Titan Medical Inc. - Ordinary Shares (TMDI) | 552 | -0.06% | 43% |
| Exelixis, Inc. (EXEL) | 548 | -0.02% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Eagle Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled EGRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 555 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of EGRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EGRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.